Nemaura executive touts sugarBEAT continuous glucose monitor at virtual diabetes conference

Nemaura Medical Inc (NASDAQ:NMRD) announced Tuesday that its vice president of Straategy and Strategic Alliances Fred Schaebsdau was a guest speaker at the DiabetesMine D-Data Virtual ExChange. Schaebsdau showcased sugarBEAT, the company’s non-invasive continuous glucose monitor (CGM) for patients with Type 2 diabetes. He also discussed the companion BEATdiabetes ecosystem, which is designed to support patients in managing their condition. The presentation underscored the versatility of the platform for continuous non-invasive monitoring, which includes temperature monitoring as well as lactate or alcohol monitoring. READ: Nemaura Medical set to enjoy investor attention as it qualifies to join the Russell 2000 and Russell 3000 Indexes Nemaura’s CGM can help Type 2 and pre-diabetic patients achieve better time-in-range,that is within recommended blood sugar levels, which subsequently can lead to better medical outcomes - all without requiring patients to prick their fingers. The DiabetesMine event is held biannually. Last week’s iteration was timed to coincide with the American Diabetes Association’s Scientific Sessions, attracting a large number of attendees, including diabetes advocates, pharma leaders, developers, clinicians and others. Nemaura’s SugarBEAT device has already received its CE mark from regulators in Europe and is currently in production in the UK. Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com Follow him on Twitter @andrew_kessel